Taiwan's losses from Typhoon Megi at least $31.89m
Staff Writer |
Taiwan's agricultural losses from Typhoon Megi, which battered much of Taiwan on Tuesday, had reached at least NT$1 billion ($31.89 million) as of Wednesday, according to an initial estimate released by the Council of Agriculture (COA).
Article continues below
As of 5 p.m., agricultural losses as a result of the damage caused by the storm had reached NT$1.03 billion, with Yunlin County in the central-south part of western Taiwan suffering the heaviest losses, the COA said.
Typhoon Megi made landfall Tuesday in Hualien County, eastern Taiwan, causing four deaths and 527 injuries and leaving more than 3.64 million households without power before moving away toward China early Wednesday.
Crop damage accounted for most of the losses, according to the COA, with 18,570 hectares of farmland and NT$964.75 million-worth of crops damaged.
The COA said banana growers took the biggest hit, suffering crop losses of NT$136.51 million and damage to 294 hectares of farmland.
Growers of rice and guavas, persimmons and taro also suffered heavy losses, the COA said.
The livestock sector faced NT$3.25 million in losses, largely due to losses of chickens, ducks and pigs, the COA said.
The COA said damage to agricultural facilities totaled at least NT$55.45 million as of Wednesday evening, with Kaohsiung, Yunlin and Tainan suffering most of the losses. Damage to livestock and poultry breeding facilities was at least NT$4.6 million, mainly due to losses in Taichung and Tainan.
Vegetable prices in the local wholesale market jumped about 65 percent Thursday from a day earlier after Typhoon Megi damaged local transportation facilities, leading to difficulties in delivery and a drop in supplies, according to the Agriculture and Food Agency (AFA) under the Council of Agriculture. ■
The Menarini Group announced that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.